– USA, GA & MA – Inhibikase Therapeutics, Inc. announces the election of Dr. Hilary Malone, current Chief Regulatory Officer, Sanofi, to its Board of Directors. Dr. Steven R. Gilman has retired from the Board after nearly four-and-one-half years of service.
Dr. Malone has over 20 years’ experience in drug development and global regulatory affairs and currently serves as the Head of Global Regulatory Affairs for Sanofi, a position she has held since 2013. Prior to joining Sanofi, Dr. Malone held roles as the Senior Vice-President and Head of Worldwide Regulatory Strategy for both Pfizer and Wyeth, overseeing all human health businesses. Hilary has also worked in the small biotech arena with Reata Pharmaceuticals, where she was Chief Regulatory & Compliance Officer, from which she retired before joining Sanofi. Dr. Malone has successfully led the regulatory approval of numerous products across multiple therapeutic areas to include cardiovascular & diabetes, renal, neurological and infectious disease franchises for Wyeth, Pfizer and Sanofi. Dr. Malone has a B.Sc. (Hons.) and Ph.D. from the University of Dundee, Scotland and conducted post-doctoral research in Dundee and at the University of California, San Francisco, prior to entering the pharmaceutical industry.
“I have been impressed by the progress that Inhibikase has made in bringing its pipeline of drug candidates to the clinic. I believe that the company’s lead product has great potential to address the development of PML and I look forward to working with the Inhibikase Board and management to advance the portfolio and growth of the company.”
“As Inhibikase completes the transition to the clinic with its novel treatments for infectious disease, such as IkT-001Pro for Progressive Multifocal Leukoencephalopathy (PML), Dr. Malone’s regulatory expertise will become invaluable to Inhibikase as it advances its discussion with U.S. and European regulators on the approval path for our novel products. Hilary brings unprecedented regulatory expertise into the Company at a critical time in its development,” said Company President & CEO, Dr. Milton Werner.
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics is transforming the way pharmaceuticals attack infectious diseases. Its small molecule platform enables treatment of bacterial AND viral infectious disease through a common mechanism of action. The Company’s host-targeting strategy using clinically validated targets treat infectious disease with a low likelihood of stimulating resistance. Founded in 2008 and headquartered in Atlanta, Georgia with offices in Cambridge, Massachusetts, Inhibikase Therapeutics is developing treatments for orphan indications arising from polyomaviruses, such as progressive multifocal leukoencephalopathy (PML), BK-virus associated nephropathy (PVAN), fungal and bacterial pneumonias as well as medical countermeasures for biodefense. Its RAMP technology is developing next generation small molecule inhibitors suitable for treatment of infections, for Parkinson’s and other degenerative disorders of the CNS and certain cancers using single agents at a fixed dose.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
